Perspectives
Nature Reviews Cancer 4, 901-909 (November 2004) | doi:10.1038/nrc1473
Opinion: The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies
Richard J. Epstein1 About the author
Abstract
Dose-dense adjuvant breast cancer chemotherapy is a new treatment strategy that aims to improve tumour control by using more frequent cytotoxic dosing together with continuous granulocyte colony-stimulating factor (G-CSF) to minimize neutropaenia. In addition to stimulating neutrophil proliferation, G-CSF mobilizes neutrophils from the bone marrow through proteolytic disruption of the chemokine receptor CXCR4 and its chemotactic ligand CXCL12. As breast cancers also express CXCR4 and oestrogen induces CXCL12, the success of dose-dense treatment could partly reflect inhibition of CXCR4-dependent micrometastatic homing and/or paracrine survival, and suggests a benefit of adjuvant oestrogen suppression for patients with oestrogen-receptor-negative, CXCR4-positive disease.
Author affiliations
-
Richard J. Epstein is at the Department of Medicine, The University of Hong Kong, Room 404, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong.
Email: repstein@hku.hk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cellsNature Medicine Article (01 Jul 2006)
The CXCL12-3′A allele is associated with a higher mobilization yield of CD34 progenitors to the peripheral blood of healthy donors for allogeneic transplantationBone Marrow Transplantation Original Article
